Afternoon
Movers - AIS - Antares Pharma Announces Partners Update of LibiGel- Sourced WhisperFromWallStreet.com
http://whisperfromwallstreet.com is a FREE award winning newsletter that
specializes in sending alerts to our subscribers on stocks we think are going
to run, why we think so, as well as teaching you how to become a better trader.
We scan hundreds of stocks a day to find those that meet our criteria and when
we find one, we send you an alert. We have sent out 40 alerts so far in 2009
with an average price gain of over 80%. Please join risk free and see for
yourself.
Sign up for our FREE alerts at WhisperfromWallStreet.com
---
Antares Pharma Inc.AIS
After Hours: 1.09 Up 0.37 (51.39%) 3:22pm ET
Pharmaceuticals announced today that based upon a review of study conduct and
blinded data from the LibiGel Phase III Cardiovascular and Breast Cancer Safety
Study, the LibiGel Safety Study External Executive Committee has recommended
continuation of the LibiGel Phase III clinical program. A very low
cardiovascular event rate has occurred thus far in the LibiGel Phase III
clinical studies.
The Executive Committee evaluated study information from over 1,000 women
enrolled totaling approximately 600 women-years of exposure in the Phase III
LibiGel safety study. All serious adverse events including those in the
cardiovascular categories as well as non-serious adverse events have been
reviewed by the committee.
About
Antares Pharma, Inc. operates as a specialty drug delivery/pharmaceutical
company. Its drug delivery platforms include Advanced Transdermal Delivery
gels, disposable pressure assisted auto injection systems, reusable needle-free
injection systems, disposable pen injection systems, and oral disintegrating
tablets. The company?s transdermal systems consist of semisolid dosage forms,
which deliver medication and minimize gastrointestinal impact, as well as the
initial liver metabolism effect of orally ingested drugs. Its injection device
platform offers reusable needle-free injectors, which deliver precise
medication doses through pressurized liquid penetration of the skin without a
needle; disposable pressure assisted auto injectors that provide subcutaneous
injections with minimal discomfort and safety of a shielded needle; and
disposable pen injectors, which are needle-based devices designed to deliver
multiple injections from multi-dose drug cartridges.
Last Trade: 1.12
Day's Range: 0.98 - 1.21
52wk Range: 0.29 - 0.90
Volume: 9,815,586
---
Here are a few alerts our WhisperfromWallStreet.com subscribers enjoyed.
SPNG 1000%
AMNG 241%
RKBD 300%
UTRM 169%
TLLE 266%
Sign up to receive free
stock alerts
---
Disclaimer: Full disclaimer at
http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable
herein prepared all material. The information contained herein is not guaranteed
by WFWS to be accurate, and should not be considered to be all-inclusive. The
companies that are discussed in this opinion have not approved the statements
made in this opinion. This opinion contains forward-looking statements that
involve risks and uncertainties. This material is for informational purposes
only and should not be construed as an offer or solicitation of an offer to buy
or sell securities. WFWS is not a licensed broker, broker dealer, market maker,
investment banker, investment advisor, analyst or underwriter. Please consult a
broker before purchasing or selling any securities viewed on
http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have
been compensated with shares or with cash from third party shareholders or the
company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking statements
are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. "Forward-looking statements" describe
future expectations, plans, results, or strategies and are generally preceded
by words such as "may", "future", "plan" or
"planned", "will" or "should",
"expected," "anticipates", "draft",
"eventually" or "projected". You are cautioned that such
statements are subject to a multitude of risks and uncertainties that could
cause future circumstances, events, or results to differ materially from those
projected in the forward-looking statements, including the risks that actual
results may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks identified in a
companies' annual report on Form 10-K or 10-KSB and other filings made by such
company with the Securities and Exchange Commission. You should consider these
factors in evaluating the forward-looking statements included herein, and not
place undue reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and WFWS undertakes no obligation to
update such statements.
This is not a solicitation to buy or sell any securities.
WhisperfromWallStreet.com, nor any of its affiliates are not registered
investment advisors or a broker dealers. Never invest in any stock featured on
our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
